淋巴细胞亚群动态监测在ANCA相关性血管炎全过程治疗中的作用

doi:10.3969/j.issn.1004-583X.2026.02.007

摘要/Abstract

摘要：

目的分析抗中性粒细胞胞浆抗体相关性血管炎(antineutrophil cytoplasmic antibody associated vasculitis,AAV)患者在不同疾病阶段淋巴细胞亚群的变化特征,发现并评价其在AAV患者治疗全过程中的价值。方法纳入2015年1月1日-2024年6月30日于青岛大学附属医院就诊,在疾病初诊活动期及诱导治疗后均检测过淋巴细胞亚群的AAV患者70例,分析AAV患者活动期、缓解期和感染时淋巴细胞亚群的特点及变化规律,发现并评价其与AAV患者活动度、感染事件以及预后的内在联系。结果与初诊活动期相比,诱导治疗后AAV患者血CD4⁺T淋巴细胞计数和自然杀伤细胞比例均上升,且与伯明翰血管炎活度评分呈负相关(P=0.006,P<0.001),同时血B淋巴细胞比例下降,与伯明翰血管炎活度评分呈正相关(P<0.001)。AAV活动期最易感染,发生率高达52.8%,以肺部感染为主(71.4%)。多因素logistic回归分析显示年龄(OR=1.092,95%CI: 1.024~1.163,P=0.007)、B淋巴细胞比例(OR=1.077,95%CI:1.021~1.136,P=0.007)和C-反应蛋白(OR=1.069,95%CI:1.033~1.107,P<0.001)是AAV患者发生感染的独立危险因素。持续随访发现,就诊时为低CD4⁺T淋巴细胞计数、低自然杀伤细胞比例、高B淋巴细胞比例、高C-反应蛋白水平、高红细胞沉降率的组合像的患者与肾脏不良结局相关(P=0.042);并且在验证集中得到了相同的结果(P=0.014)。结论淋巴细胞亚群可用于判断AAV患者病情活动状态及感染易感状态,运用淋巴细胞亚群、红细胞沉降率及C-反应蛋白的联动组合可以判断AAV患者病情,精准施治。

Abstract:

Objective To characterize changes in lymphocyte subsets across different disease stages of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and to evaluate their utility throughout the course of treatment. Methods This retrospective study included 70 AAV patients who attended the Affiliated Hospital of Qingdao University between January 1, 2015 and June 30, 2024 and who had lymphocyte-subset testing performed both at initial presentation during active disease and after induction therapy. We analyzed lymphocyte subset profiles and their dynamics during active disease, remission, and episodes of infection, and explored associations with disease activity (BVAS), infection events, and clinical outcomes. Results Compared with initial active presentation, patients at after induction therapy had significantly lower blood CD4⁺ T-cell counts and lower proportions of natural killer (NK) cells; both parameters were negatively correlated with BVAS (P=0.006 and P<0.001, respectively). Peripheral B-cell proportion was lowered during active disease and correlated positively with BVAS (P<0.001).The active disease phase had the highest infection rate (52.8%), predominantly pulmonary infections (71.4%). Multivariable logistic regression identified age (OR=1.092,95%CI:1.024-1.163, P=0.007), B-cell proportion (OR=1.077, 95%CI: 1.021-1.136, P=0.007), and C-reactive protein (CRP) level (OR=1.069, 95%CI: 1.033-1.107, P<0.001) as independent risk factors for infection in AAV patients. During follow-up, patients presenting with the composite profile of low CD4⁺ T-cell count, low NK-cell proportion, high B-cell proportion, elevated CRP, and elevated erythrocyte sedimentation rate (ESR) were more likely to experience adverse renal outcomes (P=0.042); this association was confirmed in an independent validation cohort (P=0.014). Conclusion Lymphocyte subset profiling is informative for assessing disease activity and infection susceptibility in AAV. A combined biomarker approach incorporating lymphocyte subsets, ESR, and CRP can help stratify disease status and guide more precise therapeutic decisions.

Key words: anti-neutrophil cytoplasmic antibody-associated vasculitis, lymphocyte subsets, active state, infection, prognosis

中图分类号:

R543

张凯迪, 张丽君, 陈璐, 邢广群. 淋巴细胞亚群动态监测在ANCA相关性血管炎全过程治疗中的作用[J]. 临床荟萃, 2026, 41(2): 140-147.

Zhang Kaidi, Zhang Lijun, Chen Lu, Xing Guangqun. The role of dynamic lymphocyte subset monitoring in the full-course management of antineutrophil cytoplasmic antibody-associated vasculitis[J]. Clinical Focus, 2026, 41(2): 140-147.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.02.007

https://www.lchc.cn/CN/Y2026/V41/I2/140

图/表 9

参考文献 21

[1]	Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus conference nomenclature of vasculitides[J]. Arthritis Rheum, 2013, 65(1): 1-11. doi: 10.1002/art.37715.
[2]	Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis[J]. Nat Rev Rheumatol, 2019, 15(2): 91-101. doi: 10.1038/s41584-018-0145-y. pmid: 30542206
[3]	Martinez VL, Bordignon DJ, Fulladosa OX, et al. T-lymphocyte in ANCA-associated vasculitis: What do we know? A pathophysiological and therapeutic approach[J]. Clin Kidney J, 2019, 12(4): 503-511. doi: 10.1093/ckj/sfz029. pmid: 31384441
[4]	Haris Á, Polner K, Arányi J, et al. Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis[J]. Physiol Int, 2021, 108(1):66-79. doi: 10.1556/2060.2021.00006.
[5]	Caballero-Islas AE, Hoyo-Ulloa I, García-Castro A, et al. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: A retrospective cohort study with a clinical phenotype approach[J]. Rheumatol Int, 2020, 40(10): 1657-1666. doi: 10.1007/s00296-020-04661-x. pmid: 32728838
[6]	Xu T, Chen Z, Jiang M, et al. Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: A retrospective study with monthly infection screening[J]. RMD Open, 2022, 8(2): 1-13. doi: 10.1136/rmdopen-2022-002424.
[7]	Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham vasculitis activity score (version 3)[J]. Ann Rheum Dis, 2009, 68(12):1827-1832. doi:10.1136/ard.2008.101279. pmid: 19054820
[8]	Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides[J]. Arthritis Rheum, 1997, 40(2):371-380. doi: 10.1002/art.1780400222.
[9]	张丽君, 公智卿, 韩润鸿, 等. 淋巴细胞亚群及血细胞比值动态监测对狼疮性肾炎病情判断的价值[J]. 中华全科医师杂志, 2023, 22(12): 1288-1294. doi:10.3760/cma.j.cn114798-20231014-00242.
[10]	Patel NJ, Stone JH. Expert perspective: Management of antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Rheumatol, 2022, 74(8): 1305-1317. doi: 10.1002/art.42114.
[11]	Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis[J]. Kidney Int, 2024, 105(3S):S71-S116.doi: 10.1016/j.kint.2023.10.008.
[12]	中华医学会肾脏病学分会专家组. 抗中性粒细胞胞质抗体相关肾炎诊断和治疗中国指南[J]. 中华肾脏病杂志, 2021, (7): 603-620. doi: 10.3760/cma.j.cn441217-20210107-00092.
[13]	London J, Dumoitier N, Lofek S, et al. Skewed peripheral B- and T-cell compartments in patients with ANCA-associated vasculitis[J]. Rheumatology (Oxford), 2021, 60(5): 2157-2168. doi: 10.1093/rheumatology/keaa432. pmid: 33026090
[14]	Abdulahad WH, Kallenberg CG, Limburg PC, et al. Urinary CD4⁺ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Rheum, 2009, 60(9): 2830-2838. doi: 10.1002/art.24747.
[15]	Krebs CF, Reimers D, Zhao Y, et al. Pathogen-induced tissue-resident memory T(H)17 (T(RM)17) cells amplify autoimmune kidney disease[J]. Sci Immunol, 2020, 5(50): 1-15. doi: 10.1126/sciimmunol.aba4163.
[16]	Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells[J]. Science, 2011, 331(6013): 6. doi: 10.1126/science.1198687.
[17]	Urlaub D, Zhao S, Blank N, et al. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis[J]. Arthritis Res Ther, 2019, 21(1): 277. doi: 10.1186/s13075-019-2054-0.
[18]	Merkt W, Salzer U, Thiel J, et al. Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides[J]. BMC Immunol, 2021, 22(1): 26. doi: 10.1186/s12865-021-00416-w.
[19]	Mcclure M, Gopaluni S, Jayne D, et al. B cell therapy in ANCA-associated vasculitis: Current and emerging treatment options[J]. Nat Rev Rheumatol, 2018, 14(10): 580-591. doi: 10.1038/s41584-018-0065-x. pmid: 30108367
[20]	张丽君, 李远, 田芬, 等. 重度活动性狼疮性肾炎冲击治疗淋巴细胞亚群及血细胞比值变化[J]. 青岛大学学报(医学版), 2023, 59(6): 802-807. doi: 10.11712/jms.2096-5532.2023.59.199.
[21]	Luan JJ, Xing GQ. Pathogenesis of antimicrobial peptides LL-37 and CpG-ODN in ANCA associated vasculitis[J]. J Nephrol, 2017, 30(1): 63-71. doi: 10.1007/s40620-016-0336-z.

项目	初诊时	诱导治疗后	t/Z/χ²值	P值
BVAS评分(分)	18.49±4.23	9.54±3.81	-5.063	<0.001
eGFR[ml/(min·1.73 m²)]	39.74(22.61,71.98)	69.22(35.24,119.70)	-4.690	<0.001
血肌酐(μmol/L)	376.70(104.35,579.25)	212.00(106.82,276.12)	-2.272	0.023
CD4⁺T淋巴细胞计数(cell/μl)	244.00(190.50,386.00)	474.50(358.50,838.00)	-2.424	0.015
NK细胞(%)	3.67(1.48,7.64)	5.66(4.71,18.36)	-2.871	0.006
CD8⁺T淋巴细胞(%)	28.90(19.15,41.51)	21.23(19.58,28.07)	-2.389	0.017
CD4⁺T淋巴细胞(%)	41.66(23.71,54.89)	47.89(32, 14,72.11)	-4.622	<0.001
B淋巴细胞(%)	20.87(1.54,29.29)	9.17(4.22,20.57)	-3.615	<0.001
静止T细胞(%)	54.20(47.03,62.09)	57.96(48.08,68.65)	-1.415	0.157
活化T细胞(%)	13.40(10.07,20.99)	12.14(9.14,22.82)	-0.223	0.823
活化T感染细胞(%)	3.07(1.48,4.45)	1.74(1.02,2.88)	-1.336	0.182
白蛋白(g/L)	29.30(28.20,32.22)	32.80(29.70,35.02)	-3.623	<0.001
D-二聚体(μg/L)	440.00(250.00,1960.00)	420.00(267.50,495.00)	-2.823	0.005
ESR(mm/h)	35.50(21.50,106.00)	12.00(10.00,64.12)	-2.228	0.026
CRP(mg/L)	14.67(6.51,26.03)	0.94(0.50,21.23)	-2.965	0.003
降钙素原(μg/L)	0.13(0.07,0.51)	0.14(0.09,0.16)	-1.087	0.282
血白细胞计数(×10⁹/L)	6.73(5.95,8.48)	11.25(8.55,14.25)	-0.295	0.693
血淋巴细胞计数(×10⁹/L)	0.50(0.47,1.13)	1.05(0.65,1.64)	-2.941	0.003
血红蛋白(g/L)	83.53(64.05,102.08)	103.05(82.57,122.76,)	3.095	0.002
血小板计数(×10⁹/L)	187.00(164.00,278.50)	199.00(174.25,228.75)	-1.311	0.190
尿红细胞计数(个/μl)	587.80(5.47,587.80)	148.00(6.05,266.60)	-3.406	0.001
24 h尿蛋白定量(mg/d)	1 292.80(347.30,2 040.00)	274.90(221.50,631.72)	-4.042	<0.001
补体C3(g/L)	0.74(0.62,0.87)	1.03(0.79,1.26)	-2.887	0.004
补体C4(g/L)	0.19(0.16,0.23)	0.29(0.26,0.37)	-3.211	0.001
IgA(g/L)	2.08(0.84,2.46)	2.11(0.80,2.33)	1.732	0.084
IgM(g/L)	1.28(0.65,2.23)	1.15(0.56,1.96)	1.447	0.140
IgG(g/L)	13.58(3.05,19, 45)	10.34(3.96,18.49)	0.821	0.430
IgE(g/L)	36.54(19.84,54.00)	26.70(15.70,62.75)	1.703	0.098
感染[例(%)]	28(52.8)	16(30.2)	4.262	0.039
MPO-ANCA[例(%)]			14.566	<0.002
+++	21(42.9)	5(10.2)
++	6(12.2)	13(26.5)
+	10(20.4)	14(28.6)
-	12(24.5)	17(34.7)
PR3-ANCA[例(%)]			-	0.429
阳性	4(100.0)	2(50.0)
阴性	0	2(50.0)

项目	初诊时	诱导治疗后	t/Z/χ²值	P值
BVAS评分(分)	18.49±4.23	9.54±3.81	-5.063	<0.001
eGFR[ml/(min·1.73 m²)]	39.74(22.61,71.98)	69.22(35.24,119.70)	-4.690	<0.001
血肌酐(μmol/L)	376.70(104.35,579.25)	212.00(106.82,276.12)	-2.272	0.023
CD4⁺T淋巴细胞计数(cell/μl)	244.00(190.50,386.00)	474.50(358.50,838.00)	-2.424	0.015
NK细胞(%)	3.67(1.48,7.64)	5.66(4.71,18.36)	-2.871	0.006
CD8⁺T淋巴细胞(%)	28.90(19.15,41.51)	21.23(19.58,28.07)	-2.389	0.017
CD4⁺T淋巴细胞(%)	41.66(23.71,54.89)	47.89(32, 14,72.11)	-4.622	<0.001
B淋巴细胞(%)	20.87(1.54,29.29)	9.17(4.22,20.57)	-3.615	<0.001
静止T细胞(%)	54.20(47.03,62.09)	57.96(48.08,68.65)	-1.415	0.157
活化T细胞(%)	13.40(10.07,20.99)	12.14(9.14,22.82)	-0.223	0.823
活化T感染细胞(%)	3.07(1.48,4.45)	1.74(1.02,2.88)	-1.336	0.182
白蛋白(g/L)	29.30(28.20,32.22)	32.80(29.70,35.02)	-3.623	<0.001
D-二聚体(μg/L)	440.00(250.00,1960.00)	420.00(267.50,495.00)	-2.823	0.005
ESR(mm/h)	35.50(21.50,106.00)	12.00(10.00,64.12)	-2.228	0.026
CRP(mg/L)	14.67(6.51,26.03)	0.94(0.50,21.23)	-2.965	0.003
降钙素原(μg/L)	0.13(0.07,0.51)	0.14(0.09,0.16)	-1.087	0.282
血白细胞计数(×10⁹/L)	6.73(5.95,8.48)	11.25(8.55,14.25)	-0.295	0.693
血淋巴细胞计数(×10⁹/L)	0.50(0.47,1.13)	1.05(0.65,1.64)	-2.941	0.003
血红蛋白(g/L)	83.53(64.05,102.08)	103.05(82.57,122.76,)	3.095	0.002
血小板计数(×10⁹/L)	187.00(164.00,278.50)	199.00(174.25,228.75)	-1.311	0.190
尿红细胞计数(个/μl)	587.80(5.47,587.80)	148.00(6.05,266.60)	-3.406	0.001
24 h尿蛋白定量(mg/d)	1 292.80(347.30,2 040.00)	274.90(221.50,631.72)	-4.042	<0.001
补体C3(g/L)	0.74(0.62,0.87)	1.03(0.79,1.26)	-2.887	0.004
补体C4(g/L)	0.19(0.16,0.23)	0.29(0.26,0.37)	-3.211	0.001
IgA(g/L)	2.08(0.84,2.46)	2.11(0.80,2.33)	1.732	0.084
IgM(g/L)	1.28(0.65,2.23)	1.15(0.56,1.96)	1.447	0.140
IgG(g/L)	13.58(3.05,19, 45)	10.34(3.96,18.49)	0.821	0.430
IgE(g/L)	36.54(19.84,54.00)	26.70(15.70,62.75)	1.703	0.098
感染[例(%)]	28(52.8)	16(30.2)	4.262	0.039
MPO-ANCA[例(%)]			14.566	<0.002
+++	21(42.9)	5(10.2)
++	6(12.2)	13(26.5)
+	10(20.4)	14(28.6)
-	12(24.5)	17(34.7)
PR3-ANCA[例(%)]			-	0.429
阳性	4(100.0)	2(50.0)
阴性	0	2(50.0)

项目	感染组(n=28)	非感染组(n=25)	Z/χ²值	P值
年龄(岁)	67.00(62.00, 70.5)	63.00(57.00, 68.00)	-3.708	<0.001
BVAS评分(分)	17.61(12.50,23.20)	14.54(12.21,20.89)	-2.260	0.024
eGFR[ml/(min·1.73 m²)]	46.74(26.61, 71.98)	57.22(37.24, 119.70)	-2.871	0.006
血肌酐(μmol/L)	312.00(106.82,476.12)	244.70(102.36,569.25)	-2.272	0.023
CD4⁺T淋巴细胞计数(cell/μl)	290.00(160.50,386.00)	359.00(206.50,508.00)	-2.424	0.015
NK细胞(%)	5.67(1.48,7.64)	8.87(4.71,18.36)	-2.138	0.033
CD8⁺T淋巴细胞(%)	27.56(16.15,47.51)	26.06(18.02,33.53)	-0.855	0.392
CD4⁺T淋巴细胞(%)	42.73(34.27,51.85)	46.83(31, 14,71.51)	-2.389	0.017
B淋巴细胞(%)	13.87(5.54,25.43)	9.86(4.98,16.73)	-2.049	0.040
静止T细胞(%)	41.61(39.25, 65.15)	64.43(41.31, 73.33)	-2.450	0.014
活化T细胞(%)	9.40(5.43,16.04)	10.14(8.14,22.82)	-0.223	0.823
活化T感染细胞(%)	8.29(6.32,13.25)	6.74(3.05,11.88)	-1.336	0.182
白蛋白(g/L)	30.90(26.41,34.40)	32.80(28.90,36.10)	-1.356	0.176
D-二聚体(μg/L)	620.00(360.00,2260.00)	320.00(240.50,560.00)	-2.330	0.019
ESR(mm/h)	46.00(31.30,79.17)	17.00(11.75,47.00)	-2.242	0.024
CRP(mg/L)	7.67(5.51,32.03)	1.67(0.51,4.54)	-4.152	0.001
降钙素原(μg/L)	0.26(0.11,1.04)	0.09(0.04,0.18)	-2.361	0.018
血白细胞计数(×10⁹/L)	8.73(5.95,11.61)	7.14(6.37,9.25)	-2.250	0.024
血淋巴细胞计数(×10⁹/L)	0.96(0.45,1.24)	1.30(0.65,1.80)	-3.042	0.002
血红蛋白(g/L)	87.53(64.05,102.08)	94.05(82.57,116.76)	-2.171	0.030
血小板计数(×10⁹/L)	187.00(164.00,278.50)	199.00(174.25,228.75)	-1.311	0.190
尿红细胞计数(个/μl)	387.80(5.47,587.80)	148.00(6.05,266.60)	-3.406	0.001
24 h尿蛋白定量(mg/d)	892.80(347.30,1 392.00)	669.90(221.50,1 031.72)	-4.042	0.001
补体C3(g/L)	0.94(0.62,1.14)	0.92(0.79,1.18)	-0.581	0.561
补体C4(g/L)	0.19(0.16,0.23)	0.23(0.17,0.37)	-0.721	0.471
IgA(g/L)	2.00(0.80,2.56)	2.09(0.82,2.23)	1.732	0.084
IgM(g/L)	1.28(0.65,2.23)	1.25(0.62,1.96)	0.807	0.422
IgG(g/L)	11.58(3.05,19, 45)	10.73(3.96,18.49)	-1.350	0.176
IgE(g/L)	32.70(19.84,54.00)	29.43(17.70,56.75)	1.703	0.098
MPO-ANCA[例(%)]			5.580	0.134
+++	10(40.0)	3(12.5)
++	3(12.0)	6(25.0)
+	6(24.0)	6(25.0)
-	6(24.0)	9(37.5)
PR3-ANCA[例(%)]			-	-
阳性	3(100.0)	1(100.0)
阴性	0	0

项目	感染组(n=28)	非感染组(n=25)	Z/χ²值	P值
年龄(岁)	67.00(62.00, 70.5)	63.00(57.00, 68.00)	-3.708	<0.001
BVAS评分(分)	17.61(12.50,23.20)	14.54(12.21,20.89)	-2.260	0.024
eGFR[ml/(min·1.73 m²)]	46.74(26.61, 71.98)	57.22(37.24, 119.70)	-2.871	0.006
血肌酐(μmol/L)	312.00(106.82,476.12)	244.70(102.36,569.25)	-2.272	0.023
CD4⁺T淋巴细胞计数(cell/μl)	290.00(160.50,386.00)	359.00(206.50,508.00)	-2.424	0.015
NK细胞(%)	5.67(1.48,7.64)	8.87(4.71,18.36)	-2.138	0.033
CD8⁺T淋巴细胞(%)	27.56(16.15,47.51)	26.06(18.02,33.53)	-0.855	0.392
CD4⁺T淋巴细胞(%)	42.73(34.27,51.85)	46.83(31, 14,71.51)	-2.389	0.017
B淋巴细胞(%)	13.87(5.54,25.43)	9.86(4.98,16.73)	-2.049	0.040
静止T细胞(%)	41.61(39.25, 65.15)	64.43(41.31, 73.33)	-2.450	0.014
活化T细胞(%)	9.40(5.43,16.04)	10.14(8.14,22.82)	-0.223	0.823
活化T感染细胞(%)	8.29(6.32,13.25)	6.74(3.05,11.88)	-1.336	0.182
白蛋白(g/L)	30.90(26.41,34.40)	32.80(28.90,36.10)	-1.356	0.176
D-二聚体(μg/L)	620.00(360.00,2260.00)	320.00(240.50,560.00)	-2.330	0.019
ESR(mm/h)	46.00(31.30,79.17)	17.00(11.75,47.00)	-2.242	0.024
CRP(mg/L)	7.67(5.51,32.03)	1.67(0.51,4.54)	-4.152	0.001
降钙素原(μg/L)	0.26(0.11,1.04)	0.09(0.04,0.18)	-2.361	0.018
血白细胞计数(×10⁹/L)	8.73(5.95,11.61)	7.14(6.37,9.25)	-2.250	0.024
血淋巴细胞计数(×10⁹/L)	0.96(0.45,1.24)	1.30(0.65,1.80)	-3.042	0.002
血红蛋白(g/L)	87.53(64.05,102.08)	94.05(82.57,116.76)	-2.171	0.030
血小板计数(×10⁹/L)	187.00(164.00,278.50)	199.00(174.25,228.75)	-1.311	0.190
尿红细胞计数(个/μl)	387.80(5.47,587.80)	148.00(6.05,266.60)	-3.406	0.001
24 h尿蛋白定量(mg/d)	892.80(347.30,1 392.00)	669.90(221.50,1 031.72)	-4.042	0.001
补体C3(g/L)	0.94(0.62,1.14)	0.92(0.79,1.18)	-0.581	0.561
补体C4(g/L)	0.19(0.16,0.23)	0.23(0.17,0.37)	-0.721	0.471
IgA(g/L)	2.00(0.80,2.56)	2.09(0.82,2.23)	1.732	0.084
IgM(g/L)	1.28(0.65,2.23)	1.25(0.62,1.96)	0.807	0.422
IgG(g/L)	11.58(3.05,19, 45)	10.73(3.96,18.49)	-1.350	0.176
IgE(g/L)	32.70(19.84,54.00)	29.43(17.70,56.75)	1.703	0.098
MPO-ANCA[例(%)]			5.580	0.134
+++	10(40.0)	3(12.5)
++	3(12.0)	6(25.0)
+	6(24.0)	6(25.0)
-	6(24.0)	9(37.5)
PR3-ANCA[例(%)]			-	-
阳性	3(100.0)	1(100.0)
阴性	0	0

变量	赋值
因变量(Y)
是否发生感染	是=1,否=0
自变量(X)
年龄	连续变量
CD4⁺T淋巴细胞计数	连续变量
NK细胞比例	连续变量
B细胞比例	连续变量
CRP	连续变量
ESR	连续变量